Docoh
Loading...

MDWD MediWound

News

Pro users get this 30m faster
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
6 Oct 21
Biotech, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)
MediWound Announces Peer-Reviewed Publication Of EscharEx In-Vivo Head-To-Head Comparator Study In The Journal Of Wound Care
4 Oct 21
News
MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced a peer-reviewed publication in the
Aegis Capital Maintains Buy on MediWound, Lowers Price Target to $9
17 Aug 21
News, Price Target, Analyst Ratings
Aegis Capital maintains MediWound (NASDAQ:MDWD) with a Buy and lowers the price target from $10 to $9.
HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $6.5
11 Aug 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:MDWD) with a Buy and lowers the price target from $7 to $6.5.
MediWound Q2 EPS $(0.12) Misses $(0.07) Estimate, Sales $6.10M Beat $5.63M Estimate
10 Aug 21
Earnings, News
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.07) by 71.43 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the
Earnings Scheduled For August 10, 2021
10 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
MediWound's Earnings: A Preview
9 Aug 21
Earnings
On Tuesday, August 10, MediWound (NASDAQ:MDWD) will release its latest earnings report. Benzinga's outlook for MediWound is included in the following report.
MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
28 Jul 21
News
Independent Data Monitoring Committee Recommends Continuation of the Study with No Changes to Study Sample Size No Safety Concerns
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
26 Jul 21
Biotech, News, Penny Stocks, Health Care, General